TY - JOUR
T1 - A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
T2 - Screening experience and baseline characteristics
AU - Ford, Ian
AU - Blauw, Gerard Jan
AU - Murphy, Michael B.
AU - Shepherd, James
AU - Cobbe, Stuart M.
AU - Bollen, Edward L E M
AU - Buckley, Brendan M.
AU - Jukema, J. Wouter
AU - Hyland, Michael
AU - Gaw, Allan
AU - Lagaay, A. Margot
AU - Perry, Ivan J.
AU - Macfarlane, Peter W.
AU - Norrie, John
AU - Meinders, A. Edo
AU - Sweeney, Brian J.
AU - Packard, Chris J.
AU - Westendorp, Rudi G J
AU - Twoney, Cillian
AU - Stott, David J.
AU - Percy, Melvyn J.
AU - Belder, Rene
AU - McLaughlin, Christine
AU - Percy, Melvyn J.
AU - McGowan, David
AU - Anderson, Elizabeth
AU - Kean, Sharon
AU - Innes, Catherine
AU - Brown, William Virgil
AU - Diener, Hans Christoph
AU - Feely, John
AU - van Zwieten, Pieter A.
AU - Pocock, Stuart
AU - Pearson, Thomas
PY - 2002/5/20
Y1 - 2002/5/20
N2 - Background: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. Methods: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. Results: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). Conclusions: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.
AB - Background: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. Methods: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. Results: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). Conclusions: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.
KW - Baseline characteristics
KW - Clinical trial
KW - Elderly
KW - Pravastatin
UR - http://www.scopus.com/inward/record.url?scp=0003129627&partnerID=8YFLogxK
U2 - 10.1186/1468-6708-3-8
DO - 10.1186/1468-6708-3-8
M3 - Article
AN - SCOPUS:0003129627
SN - 1468-6694
VL - 3
JO - Current Controlled Trials in Cardiovascular Medicine
JF - Current Controlled Trials in Cardiovascular Medicine
M1 - 8
ER -